Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members, Cancer Cell, vol.9, issue.5, pp.351-365, 2006. ,
DOI : 10.1016/j.ccr.2006.03.027
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, issue.26, pp.4111-4119, 2014. ,
DOI : 10.1182/blood-2014-03-560284
BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, p.75, 2015. ,
Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death, Molecular Cell, vol.57, issue.5, pp.860-872, 2015. ,
DOI : 10.1016/j.molcel.2015.01.018
Venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory multiple myeloma: phase I savety and efficacy, Haematologica, pp.100-658, 2015. ,
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death and Disease, vol.15, issue.1, p.1590, 2015. ,
DOI : 10.1172/JCI39964
BH3 profiling in whole cells by fluorimeter or FACS, Methods, vol.61, issue.2, pp.61-156, 2013. ,
DOI : 10.1016/j.ymeth.2013.04.006
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, pp.202-208 ,
DOI : 10.1038/leu.2009.151
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.21, issue.1, pp.210-212 ,
DOI : 10.1038/leu.2013.216
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics, Leukemia, vol.120, issue.3, pp.761-764, 2016. ,
DOI : 10.1016/j.ymeth.2013.04.006
URL : https://hal.archives-ouvertes.fr/inserm-01411102